A phase II study of gemcitabine by fixed-dose rate infusion, cisplatin, and celecoxib in metastatic pancreatic cancer.

被引：0
|
作者：
Kobrossy, B
El-Rayes, BF
Shields, AF
Vaishampayan, U
Heilbrun, L
Zalupski, MM
Philip, PA
机构：
[1] Karmanos Canc Inst, Detroit, MI USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4120
引用
收藏
页码：343S / 343S
页数：1
相关论文
共 50 条
  • [1] A phase II study of gemcitabine (GEM) given at fixed-dose rate (FDR) infusion, low-dose cisplatin (CDDP), and bevacizumab in metastatic pancreatic cancer (PanCa).
    Ko, A. H.
    Dito, E.
    Schillinger, B.
    Hajnal, R.
    Venook, A. P.
    Bergsland, E. K.
    Allen, J.
    Rajpal, S.
    Tempero, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 188S - 188S
  • [2] A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabinefirinotecan in patients with metastatic pancreatic cancer (CALGB 89904).
    Kulke, MH
    Niedzwiecki, D
    Tempero, MA
    Hollis, DR
    Mayer, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 316S - 316S
  • [3] A phase II trial of gemcitabine and celecoxib for metastatic pancreatic cancer.
    Xiong, HQ
    Hess, KR
    Kayaleh, OR
    Goodwin, JW
    Banerjee, T
    Sinclair, SS
    Fisch, MJ
    Wolff, RA
    Abbruzzese, JL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 351S - 351S
  • [4] Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas
    Ko, AH
    Dito, E
    Schillinger, B
    Venook, AP
    Bergsland, EK
    Tempero, MA
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) : 379 - 385
  • [5] A phase II study of fixed-dose rate (FDR) genicitabine plus cisplatin for metastatic pancreatic adenocarcinoma (PanCa).
    Ko, AH
    Dito, E
    Schillinger, B
    Venook, AP
    Bergsland, EK
    Allen, J
    Tempero, MA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 340S - 340S
  • [6] A phase II study of fixed-dose rate gemcitabine plus lowdose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer
    Ko, Andrew H.
    Quivey, Jeanne M.
    Venook, Alan P.
    Bergsland, Emily K.
    Dito, Elizabeth
    Schillinger, Brian
    Tempero, Margaret A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (03): : 809 - 816
  • [7] A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer
    Basil F. El-Rayes
    Mark M. Zalupski
    Anthony F. Shields
    Ann Marie Ferris
    Ulka Vaishampayan
    Lance K. Heilbrun
    Raghu Venkatramanamoorthy
    Volkan Adsay
    Philip A. Philip
    Investigational New Drugs, 2005, 23 : 583 - 590
  • [8] A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer
    El-Rayes, BF
    Zalupski, MM
    Shields, AF
    Ferris, AM
    Vaishampayan, U
    Heilbrun, LK
    Venkatramanamoorthy, R
    Adsay, V
    Philip, PA
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (06) : 583 - 590
  • [9] A phase I fixed-dose feasibility study of MK615 and gemcitabine in patients with advanced or metastatic pancreatic cancer.
    Moriyama, Ichiro
    Ikejiri, Fumiyoshi
    Kawakami, Koshi
    Inoue, Masaya
    Kumanomido, Satoshi
    Shinichiro, Matsuda
    Takahashi, Fumimasa
    Ito, Shunsuke
    Okada, Yusuke
    Mochida, Hiroshi
    Shimazaki, Yasumasa
    Ugata, Norimi
    Okada, Takahiro
    Jo, Yumi
    Onishi, Chie
    Takahashi, Tsutomu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [10] A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
    Ko, Andrew H.
    Dito, Elizabeth
    Schillinger, Brian
    Venook, Alan P.
    Xu, Zhidong
    Bergsland, Emily K.
    Wong, Derrick
    Scott, Janet
    Hwang, Jimmy
    Tempero, Margaret A.
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (05) : 463 - 471
12345